Science and Technology Overview

Using our proprietary technology, comparative analysis of the whole proteome of hundreds of patients and hundreds of controls is carried out to identify disease specific biomarkers.

Milagen’s discovery technology relies on a proprietary high-throughput screening protein immunoassay (Multiple Protein Array Technology) that enables the screening of a large number of clinical samples with a large number of antibodies in order to discover potential biomarkers with clinical application for in vitro diagnostics.

A substantial R&D effort has led to the discovery of various biomarkers that are found to be expressed in major cancers, in tissues as well as in biological fluids, including serum and urine.

Then these proprietary biomarkers are thoroughly validated in thousands of independent highly annotated clinical samples (including clinical information on disease stage, grade, and histological type and classification, according to the American Joint Committee on Cancer, AJCC) to confirm the clinical application of the biomarkers.

Finally, we have raised monoclonal antibodies to these biomarkers and further validated their reactivity in tissue, serum, and urine from cancer patients.

These new reagents are being developed to offer new tools to the IDV industry for tissue and serum based-assays.